Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Analysis tamoxifen, endoxifen, and 4-hydroxytamoxifen in dbs of breast cancer patients by lc-ms/ms

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Presentation
  • By: HARAHAP, Yahdiana (Universitas Indonesia, Indonesia)
  • Co-author(s): Yahdiana Harahap
    Baitha Palanggatan Maggadani: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Tesanika Ribka Joulin Sitorus: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Callista Andinie Mulyadi: Pharmacy, Universitas Indonesia, Depok, Indonesia
    Denni Joko Purwanto: Dharmais Cancer Hospital, Dharmais Cancer Hospital, Jakarta, Indonesia
  • Abstract:

    Background

    The antiestrogen effect of tamoxifen is highly determined by its active metabolites, 4-Hydroxytamoxifen (endoxifen) and 4-Hydroxy-N-Desmethyltamoxifen (4-OHTAM). Monitoring concentration of analyte and metabolites in DBS helps to improve effectiveness of therapy by minimizing drug toxicity and ensuring appropriate dosage regiment with

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses